Evidence map›Paper›PMID 34844974›Full record

ArticleJournal of medical genetics2022

Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors.

Andrew Lee, Xin Yang, Jonathan Tyrer, Aleksandra Gentry-Maharaj, Andy Ryan, Nasim Mavaddat, Alex P Cunningham, Tim Carver, Stephanie Archer, Goska Leslie and 12 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Polygenic risk scores in cancer.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2026
    Article
  5. ConstitutionalJCO precision oncology · 2026
    Observational
  6. Review
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Screening and prevention of ovarian cancer.The Medical journal of Australia · 2024
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 3 countries.

Andrew LeeCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.ORCID 0000-0003-0677-0252
Xin YangCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.ORCID 0000-0003-0037-3790
Jonathan TyrerCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
Aleksandra Gentry-MaharajMRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London, London, UK.
Andy RyanMRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London, London, UK.
Nasim MavaddatCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Alex P CunninghamCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Tim CarverCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Stephanie ArcherThe Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Goska LeslieCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Jatinder KalsiDepartment of Women's Cancer, University College London Institute for Women's Health, London, UK.
Faiza GabaCRUK Barts Cancer Centre, Wolfson Institute of Preventive Medicine, London, UK.
Ranjit ManchandaCRUK Barts Cancer Centre, Wolfson Institute of Preventive Medicine, London, UK.ORCID 0000-0003-3381-5057
Simon GaytherCenter for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, USA.
Susan J RamusUniversity of New South Wales, School of Women's and Children's Health, Randwick, New South Wales, Australia.ORCID 0000-0003-0005-7798
Fiona M WalterThe Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Marc TischkowitzDepartment of Medical Genetics, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.
Ian JacobsDepartment of Women's Cancer, University College London Institute for Women's Health, London, UK.
Usha MenonMRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London, London, UK.
Douglas F EastonCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Paul PharoahCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.ORCID 0000-0001-8494-732X
Antonis C AntoniouCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK aca20@medschl.cam.ac.uk.ORCID 0000-0001-9223-3116
University of Cambridge · GBMRC Clinical Trials Unit at UCL · GBBarts Health NHS Trust · GBCancer Institute of New South Wales · AUCedars-Sinai Medical Center · USLondon Women's Clinic · GBUNSW Sydney · AU

Funding

Cancer Research UK 20861Cancer Research UK A12677Medical Research Council G0801228Medical Research Council G9901012
6 · The paper itself

Abstract

backgroundEpithelial tubo-ovarian cancer (EOC) has high mortality partly due to late diagnosis. Prevention is available but may be associated with adverse effects. A multifactorial risk model based on known genetic and epidemiological risk factors (RFs) for EOC can help identify women at higher risk who could benefit from targeted screening and prevention.

methodsWe developed a multifactorial EOC risk model for women of European ancestry incorporating the effects of pathogenic variants (PVs) in

resultsBased on a currently available PRS for EOC that explains 5% of the EOC polygenic variance, the estimated lifetime risks under the multifactorial model in the general population vary from 0.5% to 4.6% for the first to 99th percentiles of the EOC risk distribution. The corresponding range for women with an affected first-degree relative is 1.9%-10.3%. Based on the combined risk distribution, 33% of

conclusionThis multifactorial risk model can facilitate stratification, in particular among women with FH of cancer and/or moderate-risk and high-risk PVs. The model is available via the CanRisk Tool (www.canrisk.org).

Indexed as

Breast NeoplasmsOvarian NeoplasmsCarcinoma, Ovarian EpithelialFemaleGenetic Predisposition to DiseaseHumansMultifactorial InheritanceRisk Factorsclinical decision-makingearly diagnosisgenetic counselinggeneticspublic health

Identifiers

PMID34844974
PMCPMC9252860
OpenAlexW3216784922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.